Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13880MR)

This product GTTS-WQ13880MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13880MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8185MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ8191MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ6589MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ3950MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ2223MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ5321MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ13162MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ14568MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aCD1919
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW